prasinezumab (RG7935) / Prothena, Roche 
Welcome,         Profile    Billing    Logout  

2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
prasinezumab (RG7935) / Roche
PASADENA, NCT03100149 / 2017-000087-15: A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

Checkmark Presentation of data from PASADENA trial for Parkinson’s disease at AD/PD
Mar 2022 - Mar 2022: Presentation of data from PASADENA trial for Parkinson’s disease at AD/PD
Checkmark Subgroup analysis data from PASADENA trial for Parkinson's disease
Feb 2021 - Feb 2021: Subgroup analysis data from PASADENA trial for Parkinson's disease
Checkmark Data from PASADENA trial for early Parkinson's disease at MDS Congress 2020
More
Active, not recruiting
2
316
Europe, US
RO7046015, PRX002; prasinezumab, Placebo
Hoffmann-La Roche, Prothena Biosciences Limited
Parkinson's Disease
11/19
09/26
PADOVA, NCT04777331 / 2020-004997-23: A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Calendar Jan 2024 - Dec 2024: Data from PADOVA trial for Parkinson's disease
Checkmark Initiation of PADOVA study in Parkinson’s disease
Apr 2021 - Apr 2021: Initiation of PADOVA study in Parkinson’s disease
Active, not recruiting
2
586
Europe, Canada, US
Prasinezumab, Placebo
Hoffmann-La Roche, Prothena Biosciences Limited
Parkinsons Disease
09/24
11/26

Download Options